HomeComparePHGUF vs KMB

PHGUF vs KMB: Dividend Comparison 2026

PHGUF yields 132.45% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHGUF wins by $13.48M in total portfolio value
10 years
PHGUF
PHGUF
● Live price
132.45%
Share price
$1.51
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.53M
Annual income
$5,443,687.21
Full PHGUF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — PHGUF vs KMB

📍 PHGUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHGUFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHGUF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHGUF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHGUF
Annual income on $10K today (after 15% tax)
$11,258.28/yr
After 10yr DRIP, annual income (after tax)
$4,627,134.13/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, PHGUF beats the other by $4,622,695.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHGUF + KMB for your $10,000?

PHGUF: 50%KMB: 50%
100% KMB50/50100% PHGUF
Portfolio after 10yr
$6.79M
Annual income
$2,724,454.78/yr
Blended yield
40.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

PHGUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
51.7
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHGUF buys
0
KMB buys
0
No recent congressional trades found for PHGUF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHGUFKMB
Forward yield132.45%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$13.53M$45.9K
Annual income after 10y$5,443,687.21$5,222.34
Total dividends collected$12.40M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: PHGUF vs KMB ($10,000, DRIP)

YearPHGUF PortfolioPHGUF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$23,945$13,245.03$11,314$614.45+$12.6KPHGUF
2$55,262$29,640.44$12,867$760.19+$42.4KPHGUF
3$123,061$63,930.66$14,713$945.27+$108.3KPHGUF
4$264,727$133,051.80$16,924$1,181.90+$247.8KPHGUF
5$550,752$267,494.95$19,596$1,486.64+$531.2KPHGUF
6$1,109,410$520,104.50$22,850$1,882.16+$1.09MPHGUF
7$2,166,203$979,134.42$26,849$2,399.80+$2.14MPHGUF
8$4,104,595$1,786,757.87$31,812$3,083.36+$4.07MPHGUF
9$7,556,038$3,164,121.24$38,033$3,994.72+$7.52MPHGUF
10$13,528,648$5,443,687.21$45,918$5,222.34+$13.48MPHGUF

PHGUF vs KMB: Complete Analysis 2026

PHGUFStock

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Full PHGUF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this PHGUF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHGUF vs SCHDPHGUF vs JEPIPHGUF vs OPHGUF vs KOPHGUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.